The FDA Reauthorization Act we are considering today provides the FDA the resources it needs to ensure innovative and lifesaving drugs and medical devices are brought to the market in a safe and expedient manner, while providing transparency and certainty to manufacturers. Further, the device inspection and regulatory improvements title reflects language I introduced with Representatives Brooks, Peters, and Butterfield, which sets forth a risk-based approach to medical device establishment inspections and improves predictability for scheduled inspections, among other provisions. Mr. Speaker, I urge my colleagues to support this legislation. I look forward to moving it through Congress and sending it to the President's desk.
Share
More from Larry Bucshon
It is clear that the Biden administration has pushed its authorities past reasonable interpretation during the COVID- 19 pandemic. With everything from eviction moratoriums and student loan forgiveness to vaccine and mask mandates being…
Again, we need to implement the HALT Fentanyl Act now. Any further delay, including the Biden administration slow- walking its implementation, is unacceptable. I again urge a ``no'' vote on this amendment, and I yield back the balance of…
I support Mr. Miller's amendment, which would require the Attorney General to issue interim final rules to implement this act 6 months after the date of enactment. Fentanyl-related substances will still be permanently placed in schedule I…
In closing, I encourage a ``yes'' vote on this bill, and I yield back the balance of my time. The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Indiana (Mr. Bucshon) that the House suspend the rules and…





